SCHEMBL4429634

SCHEMBL4429634

Cc1c(C)c(S(=O)(=O)NC(=N)NCCC[C@H](NC(=O)c2cccn(Cc3ccc4ccccc4c3)c2=O)C(=O)O)c(C)c2c1OC(C)(C)CC2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 1/20 0.38
PLG P00747 2/20 0.37
F10 P00742 1/20 0.37
PLAU P00749 1/20 0.37
KLKB1 P03952 1/20 0.37
C3AR1 Q16581 1/20 0.34
BRD4 O60885 2/20 0.33
FOLH1 Q04609 3/20 0.32
NPSR1 Q6W5P4 2/20 0.31
HTT P42858 1/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
MAPT P10636 1/20 0.31
KMT2A Q03164 1/20 0.31
PPARG P37231 1/20 0.31
PDPK1 O15530 4/20 0.31
TGM2 P21980 1/20 0.30
MTOR P42345 1/20 0.30
BRD2 P25440 1/20 0.30
BRD3 Q15059 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4993349 0.95 F2 (0.37) F2PLGF10PLAUKLKB1
SCHEMBL4430928 0.94 F2 (0.36) F2PLGF10PLAUKLKB1
SCHEMBL4994776 0.93 PLG (0.40) F2PLGF10PLAUKLKB1
SCHEMBL4439721 0.93 PLG (0.40) F2PLGF10PLAUKLKB1
SCHEMBL4439634 0.93 PLG (0.38) F2PLGF10PLAUKLKB1
SCHEMBL4995396 0.92 PLG (0.40) F2PLGF10PLAUKLKB1
SCHEMBL4992945 0.92 PLG (0.38) F2PLGF10PLAUKLKB1
SCHEMBL4428247 0.92 PLG (0.40) F2PLGF10PLAUKLKB1
SCHEMBL4990460 0.92 PLG (0.37) F2PLGF10PLAUKLKB1
SCHEMBL4438163 0.92 PLG (0.39) F2PLGF10PLAUKLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2125739-A1 MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. (US) 2009-12-02 EP disclosed
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof ENCYSIVE PHARMACEUTICALS, INC. 2008-08-07 US disclosed
WO-2008079371-A1 MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. (US) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof C3AR1, C5, C5AR1 F2 165/4885PLG 52/4885F10 432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.